Relapsed Refractory Multiple Myeloma
14
4
5
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
14.3%
2 terminated out of 14 trials
66.7%
-19.8% vs benchmark
21%
3 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
ELISA in Relapsed/Refractory MM
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma